TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8891515

Group type: EXPERIMENTAL
Intervention: Moderate, intermittent exercise (two 30-min bouts at approximately 50% VO2peak)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Heat exposure (40 degrees C, 30% relative humidity)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Seated control (3 hours)
Number of subjects: 11
Study: 1747959

Group type: EXPERIMENTAL
Intervention: lymphoblastoid interferon (lyIFN)
Number of subjects: 599
Study: 7044387

Group type: EXPERIMENTAL
Intervention: 50 mg of pirenzepine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100 mg of pirenzepine
Number of subjects: 6
Study: 31394990

Group type: EXPERIMENTAL
Intervention: Specific loss framing
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Specific gain framing
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Nonspecific loss framing
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Nonspecific gain framing
Number of subjects: 401
Study: 30703847

Group type: EXPERIMENTAL
Intervention: 50% BFR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80% BFR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100% BFR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All BFR levels
Number of subjects: 24
Study: 27778483

Group type: EXPERIMENTAL
Intervention: Pattern scanning laser trabeculoplasty (PSLT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 29
Study: 25847941

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (n = 83)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Investigator's choice (IC) chemotherapy (n = 41)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (n = 23 with gpNMB overexpression)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Investigator's choice (IC) chemotherapy (n = 11 with gpNMB overexpression)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (n = 28 with TNBC)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Investigator's choice (IC) chemotherapy (n = 11 with TNBC)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (n = 10 with gpNMB-overexpressing TNBC)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Investigator's choice (IC) chemotherapy (n = 6 with gpNMB-overexpressing TNBC)
Number of subjects: 124
Study: 24905305

Group type: EXPERIMENTAL
Intervention: Vitamin-E along with regular medicines
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care (pregabalin with oral hypoglycemic agents)
Number of subjects: 92
Study: 22822075

Group type: EXPERIMENTAL
Intervention: Calcium acetate, lanthanum carbonate, sevelamer carbonate (active therapy)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 148
Study: 20815769

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 7
Study: 18198804

Group type: EXPERIMENTAL
Intervention: Standard interventions (mask optimization, heated humidification, topical nasal therapy, sleep apnea education)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Flexible bilevel positive airway pressure
Number of subjects: 204

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 204
Study: 16310576

Group type: EXPERIMENTAL
Intervention: Soy protein (30 grams daily for 12 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Milk protein (control group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Not applicable (normolipidemic subjects)
Number of subjects: 37
Study: 12033980

Group type: EXPERIMENTAL
Intervention: High Dk Balafilcon A silicone hydrogel lens
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low Dk HEMA lens
Number of subjects: 24
Study: 9829029

Group type: EXPERIMENTAL
Intervention: Behaviour therapy (BT) plus fluvoxamine (maximum dosage 300 mg, mean dose 288.1 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Behaviour therapy (BT) plus placebo
Number of subjects: 30
Study: 7663004

Group type: EXPERIMENTAL
Intervention: Diabetic patients without microalbuminuria
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diabetic patients with microalbuminuria
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 50
Study: 2718706

Group type: EXPERIMENTAL
Intervention: halothane (H)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: enflurane (E)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: isoflurane (I)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 23
Study: 7372251

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31285228

Group type: EXPERIMENTAL
Intervention: Filociclovir (100 mg, 350 mg, or 750 mg daily for 7 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Filociclovir (750 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Filociclovir (100 mg, 350 mg, or 750 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Filociclovir (350 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Filociclovir
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28138867

Group type: EXPERIMENTAL
Intervention: Relational active music therapy treatments
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standard of care (physiotherapy and occupational therapy) + Relational active music therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 38
Study: 26497495

Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (TNT) with FOLFOX/CAPEOX before induction neoadjuvant chemotherapy (INCT) or after consolidation neoadjuvant chemotherapy (CNCT), with 5‐FU or capecitabine‐based chemoradiation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective non‐operative management (NOM) for patients with clinical complete response (cCR).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) for patients with residual tumor at the primary site.
Number of subjects: 0
Study: 23845979

Group type: EXPERIMENTAL
Intervention: Exercise (EX) - 1 hour of treadmill walking at 55-60% peak O2 uptake, performed the evening before a meal test.
Number of subjects: 28

Group type: COMPARATOR
Intervention: No Exercise (NoEX) - control condition with no exercise prior to the meal test.
Number of subjects: 28
Study: 21536947

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide
Number of subjects: 90

Group type: COMPARATOR
Intervention: midazolam (0.3 mg/kg; max 15 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 10% nitrous oxide
Number of subjects: 90
Study: 19142744

Group type: EXPERIMENTAL
Intervention: Self-reported quality of life evaluations using HRQOL questionnaires (SF-36, EQ-5D, HAQ)
Number of subjects: 1331

Group type: EXPERIMENTAL
Intervention: Cognitive interviewing techniques and semi-structured topic guides
Number of subjects: 1331
Study: 17721103

Group type: EXPERIMENTAL
Intervention: Drug conservation arm (CD4 T-cell-guided ART strategy)
Number of subjects: 5472

Group type: COMPARATOR
Intervention: Viral suppression arm (continuous ART)
Number of subjects: 5472

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 5472
Study: 16946677

Group type: EXPERIMENTAL
Intervention: Digital wide-angle photographic fundus screening
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bedside indirect ophthalmoscopy
Number of subjects: 51
Study: 14562945

Group type: EXPERIMENTAL
Intervention: Three 20 mg intramuscular injections of a preS2/S vaccine (GenHevac‐B) on days 0, 30 and 60
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no vaccine therapy)
Number of subjects: 71
Study: 10477361

Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study: 8684200

Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (FFP) 20 mL/kg followed by 10 mL/kg after 24 h
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Gelatin-based plasma substitute 20 mL/kg followed by 10 mL/kg after 24 h
Number of subjects: 776

Group type: COMPARATOR
Intervention: Glucose (control) 20 mL/kg followed by 10 mL/kg after 24 h
Number of subjects: 776
Study: 1655223

Group type: EXPERIMENTAL
Intervention: 2000 cGy RT and dactinomycin and vincristine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1000 cGy RT and dactinomycin and vincristine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1000 cGy RT and dactinomycin, vincristine, and doxorubicin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 2000 cGy RT and dactinomycin, vincristine, and doxorubicin
Number of subjects: 7
Study: 6760980

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg nocte)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pizotifen (2-3 mg per day in three administrations)
Number of subjects: 75
Study: 29528499

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1600 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 0
Study: 27464860

Group type: COMPARATOR
Intervention: Fentanyl 2 μg/kg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oxycodone 140 μg/kg (Group O/70)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oxycodone 200 μg/kg (Group O/100)
Number of subjects: 95
Study: 23847021

Group type: EXPERIMENTAL
Intervention: Increased alcohol use
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Increased anger
Number of subjects: 246
Study: 23431348

Group type: EXPERIMENTAL
Intervention: Xiaoqinglong granules (XQLG) as add-on therapy to seretide
Number of subjects: 178

Group type: COMPARATOR
Intervention: Seretide plus placebo
Number of subjects: 178
Study: 20694887

Group type: EXPERIMENTAL
Intervention: Cold beverage (4 °C)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Thermoneutral beverage (37 °C)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Thermoneutral + ice trial
Number of subjects: 7
Study: 18633426

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/HCTZ 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan high-dose combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study: 16385103

Group type: COMPARATOR
Intervention: Opioid analgesics
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Methodologic features (slow titration, flexible dosing, minimizing concomitant analgesics, fewer study sites)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Study designs with high dropout rates
Number of subjects: 29
Study: 12434959

Group type: EXPERIMENTAL
Intervention: Ear syringing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ear syringing)
Number of subjects: 0
Study: 9890409

Group type: EXPERIMENTAL
Intervention: Amrinone (1.5 mg/kg bolus in 30 min and then 10 microg/kg/min for 1 h 30 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 8
Study: 8606901

Group type: EXPERIMENTAL
Intervention: Mechanical unweighting at 20% body weight support (BWS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mechanical unweighting at 40% body weight support (BWS)
Number of subjects: 27
Study: 2015727

Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg) and propranolol (80 mg) combination
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg) and metoprolol (100 mg) combination
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg) and pindolol (5 mg) combination
Number of subjects: 8

Group type: COMPARATOR
Intervention: Beta-blockers (propranolol, metoprolol, pindolol) alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil and beta-blocker combinations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All verapamil and beta-blocker combinations
Number of subjects: 8
Study: 6175885

Group type: EXPERIMENTAL
Intervention: Script and slides
Number of subjects: 24

Group type: COMPARATOR
Intervention: Audiotape and slides
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 24
Study: 31553833

Group type: EXPERIMENTAL
Intervention: Intravenous ustekinumab 130 mg
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Intravenous ustekinumab 6 mg/kg
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Subcutaneous ustekinumab 90 mg every 12 weeks
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Subcutaneous ustekinumab 90 mg every 8 weeks
Number of subjects: 961

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 961
Study: 28475754

Group type: EXPERIMENTAL
Intervention: Five-component intervention to increase skilled birth attendant utilization
Number of subjects: 3844

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3844
Study: 25132411

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PFS usability
Number of subjects: 0
Study: 23681133

Group type: EXPERIMENTAL
Intervention: EPC-capture stent
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 60
Study: 21700611

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 5430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5430
Study: 19470045

Group type: EXPERIMENTAL
Intervention: Water-soluble nail lacquer applied once daily on the affected fingernails of the left hand for 24 consecutive weeks
Number of subjects: 30
Study: 18063204

Group type: EXPERIMENTAL
Intervention: Interpleural analgesia (IP) with 0.2% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA) with ropivacaine
Number of subjects: 60
Study: 12851662

Group type: EXPERIMENTAL
Intervention: 21 mg/day transdermal nicotine system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo transdermal system
Number of subjects: 60
Study: 10725475

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 185

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 185
Study: 8956390

Group type: EXPERIMENTAL
Intervention: 10 mg ketamine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 mg morphine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg ketamine plus 0.5 mg morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group A (10 mL saline with no additive)
Number of subjects: 40
Study: 1574977

Group type: EXPERIMENTAL
Intervention: Propofol (induced with propofol and maintained with an infusion of propofol 12 mg/kg/h for the first 15 min, followed by 8 mg/kg/h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane (induced with propofol and maintained with isoflurane 0.5-2%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (unanaesthetised)
Number of subjects: 30
Study: 2932989

Group type: EXPERIMENTAL
Intervention: Albuterol 200 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% sodium chloride placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 1 mg
Number of subjects: 8
Study: 31141805

Group type: EXPERIMENTAL
Intervention: 4‐min chemical matricectomy using phenol (CMP)
Number of subjects: 622
Study: 28971121

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 42
Study: 25864998

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing and antirotator proximal femoral nail implant (TST, Turkey)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cementless bipolar hemiarthroplasty
Number of subjects: 86
Study: 23510143

Group type: EXPERIMENTAL
Intervention: Long term calcium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intention-to-treat approach
Number of subjects: 0
Study: 21220718

Group type: EXPERIMENTAL
Intervention: Standard + Continuum curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard curriculum alone
Number of subjects: 0
Study: 19341986

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 50

Group type: COMPARATOR
Intervention: Progressive muscular relaxation
Number of subjects: 50
Study: 16889855

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 30
Study: 15191261

Group type: EXPERIMENTAL
Intervention: Partnership between advanced practice nurse (APN) and volunteer peer advisor
Number of subjects: 20
Study: 11157333

Group type: EXPERIMENTAL
Intervention: Enriched foods plus a social program
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Regular foods plus exercise
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Enriched foods plus exercise
Number of subjects: 130

Group type: COMPARATOR
Intervention: Regular foods plus a social program
Number of subjects: 130
Study: 9890197

Group type: EXPERIMENTAL
Intervention: Circulating soluble form of Fas (sFas) in DCM
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group I (sFas > or =2.06 ng/ml)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group II (sFas <2.06 ng/ml)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation of circulating sFas levels
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Comparison of left ventricular dimension between groups
Number of subjects: 33
Study: 7625255

Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Adult-led intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 2672998

Group type: EXPERIMENTAL
Intervention: buzepide metiodide and haloperidol combination
Number of subjects: 224

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 224
Study: 82401

Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 81
Study: 31307913

Group type: EXPERIMENTAL
Intervention: Genistein supplementation (2 capsules daily for 12 weeks, each containing 54 mg genistein)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (2 capsules daily for 12 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Genistein group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 54
Study: 28645227

Group type: EXPERIMENTAL
Intervention: Care management
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison practices
Number of subjects: 10
Study: 25643928

Group type: EXPERIMENTAL
Intervention: Sclerotherapy with sodium tetradecyl sulfate (STS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard treatment (continuation of previous treatments such as moisturization, packing, and cautery)
Number of subjects: 17
Study: 23760681

Group type: EXPERIMENTAL
Intervention: Microfracture at the footprint
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no microfracture)
Number of subjects: 57
Study: 21644088

Group type: EXPERIMENTAL
Intervention: Videothoracoscopic surgery (VATS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tube thoracostomy
Number of subjects: 60
Study: 19564519

Group type: EXPERIMENTAL
Intervention: W‐E Trial
Number of subjects: 2615

Group type: COMPARATOR
Intervention: OVC
Number of subjects: 2615

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 2615
Study: 16734394

Group type: EXPERIMENTAL
Intervention: Isoflavone intake (75 mg of isoflavone conjugates/day)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Walking (45 minutes/day, 3 days/week)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combination of isoflavone plus walking
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 12658208

Group type: EXPERIMENTAL
Intervention: Inhaled epoprostenol (60 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10573618

Group type: EXPERIMENTAL
Intervention: Preoperative subcutaneous heparin (Group B, 8 patients - 4 laparoscopic and 4 open)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No preoperative thromboprophylaxis (Group A, 28 patients - 16 laparoscopic and 12 open)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison between Groups A and B
Number of subjects: 36
Study: 8706070

Group type: EXPERIMENTAL
Intervention: Beta blockers and diuretics
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (38 men)
Number of subjects: 54
Study: 1831397

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (MPA) 1000 mg i.m. daily for 15 days, followed by 1000 mg weekly
Number of subjects: 105

Group type: COMPARATOR
Intervention: Estramustine 280 mg per os twice daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (MPA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Estramustine
Number of subjects: 105
Study: 6918402

Group type: EXPERIMENTAL
Intervention: Mevinolin 6.25 mg twice daily for 4 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mevinolin 12.5 mg twice daily for 4 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mevinolin 25 mg twice daily for 4 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mevinolin 50 mg twice daily for 4 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mevinolin (all doses)
Number of subjects: 59
Study: 3893605

Group type: EXPERIMENTAL
Intervention: Social intervention in families of schizophrenic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular medication (Control)
Number of subjects: 0
Study: 30370632

Group type: EXPERIMENTAL
Intervention: Minimally invasive coronally advanced flap (MICAF)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Modified coronally advanced flap (MCAF)
Number of subjects: 7
Study: 27688266

Group type: EXPERIMENTAL
Intervention: Internal characteristics (age, race, religion, religious beliefs) and external characteristics (ever sexually active, social support, type of routine HCP)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Race and religious beliefs
Number of subjects: 110
Study: 24439973

Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (AbsorbBVS)
Number of subjects: 2690

Group type: COMPARATOR
Intervention: XIENCE family everolimus-eluting metallic coronary stent system
Number of subjects: 2690